-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40

Benzinga·11/06/2026 12:11:36
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis assumes Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $40.